TL;DR: In 2026, AncestryDNA leads for genealogy (25M database, 19B historical records), 23andMe remains the only FDA-authorized option for health reports (though post-bankruptcy privacy concerns persist), and DeepDNA offers the best value for extracting health and pharmacogenomics insights from existing raw data — with full GDPR compliance and European data hosting.
23andMe vs AncestryDNA vs DeepDNA: Honest Comparison (2026)
The consumer DNA testing market looks nothing like it did two years ago. 23andMe filed for bankruptcy in March 2025. Nearly two million customers rushed to delete their genetic data. AncestryDNA still dominates genealogy but hasn't added health reports. And a new category of services — raw data analysis platforms like DeepDNA — has emerged for people who already have genetic data and want more from it.
This comparison covers what each service actually offers in 2026, where each one wins, and where each one falls short. No marketing spin — just the facts, the trade-offs, and the privacy implications that matter.
At a Glance: 23andMe vs AncestryDNA vs DeepDNA
| Feature | 23andMe | AncestryDNA | DeepDNA |
|---|---|---|---|
| Price | $99–$199 | $99 | Free upload |
| Test type | SNP genotyping | SNP genotyping | Raw data analysis |
| New sample required? | Yes | Yes | No |
| SNPs tested | ~630,000 | ~682,000 | Analyzes your existing data |
| Health reports | Yes (FDA-authorized) | No | Yes |
| Pharmacogenomics | Yes (CYP2C19, DPYD, SLCO1B1) | No | Yes |
| Ancestry estimates | Yes | Yes (best in class) | Limited |
| Database size | 15M+ customers | 25M+ customers | N/A |
| Historical records | No | 19 billion | No |
| mtDNA/Y-DNA | Yes | No (autosomal only) | Depends on raw data |
| Raw data download | Yes | Yes | N/A (you bring your own) |
| GDPR compliant | Partial | Partial | Yes |
| Headquarters | USA | USA | Europe |
23andMe in 2026: What Changed After Bankruptcy
23andMe's story took a sharp turn in March 2025. The company filed for Chapter 11 bankruptcy after years of declining revenue and a major data breach in late 2023 that exposed partial profile information of roughly 6.9 million users.
The genetic database — containing data from over 15 million customers — was acquired by TTAM Research Institute, a nonprofit entity created by 23andMe's former CEO Anne Wojcicki, for $305 million (NPR, March 2025). The service continues to operate, and existing users retain access to their accounts and reports.
But trust took a hit. Approximately two million customers deleted their data before the transfer completed (Washington Post). State attorneys general from multiple jurisdictions filed motions arguing that genetic data shouldn't transfer without explicit customer consent. A Harvard analysis noted that federal law does little to protect genetic data held by private companies outside the healthcare system (Harvard Gazette, 2025).
What 23andMe still does well: It remains the only consumer DNA service with FDA authorization across all four categories of health-related genetic tests — genetic health risk, carrier screening, pharmacogenetics, and cancer predisposition. The pharmacogenetics reports cover three key genes: CYP2C19, DPYD, and SLCO1B1 (FDA authorization, 2018–2023). If you want FDA-cleared health reports from a single test, 23andMe is still the only DTC option.
What gives users pause: The bankruptcy demonstrated that genetic data isn't protected by the same rules as medical records. Your DNA data can be transferred during a corporate sale, and your original privacy settings may not survive the transition. For a deeper look at genetic privacy in Europe, see our GDPR and genetic data guide.
AncestryDNA: Unmatched for Genealogy, No Health Insights
AncestryDNA operates in a different lane. Its core value proposition isn't genetic analysis — it's connecting your DNA to the largest genealogical ecosystem on the planet.
With over 25 million DNA samples in its database and access to 19 billion historical records (census data, immigration records, birth and death certificates), AncestryDNA excels at relative matching and ancestral origin identification. If you want to find distant cousins, trace migration patterns, or build out a family tree with documentary evidence, AncestryDNA is the clear winner.
The test uses an Illumina OmniExpress-based chip with approximately 682,000 SNP positions — actually more than 23andMe's 630,000, though the specific SNPs selected differ significantly. Only about 20% of SNP positions overlap between the two platforms, which is why uploading raw data from one to the other yields limited results.
Where AncestryDNA falls short: No health reports, no pharmacogenomics, no carrier screening, no wellness traits. AncestryDNA deliberately chose not to enter the health space, focusing entirely on ancestry and family connections. It also tests only autosomal DNA — no mitochondrial DNA or Y-chromosome analysis for deep maternal or paternal lineage tracing.
Who it's best for: People primarily interested in genealogy, family tree building, and finding biological relatives. If health insights aren't a priority and you want the largest possible relative-matching network, AncestryDNA delivers the most value per dollar.
DeepDNA: Get More from the Data You Already Have
DeepDNA takes a fundamentally different approach. Instead of asking you to spit in a new tube, it analyzes the raw data file you already have from 23andMe, AncestryDNA, or another testing service.
This matters for several reasons. First, cost: if you've already paid for a DNA test, you shouldn't need to pay again to extract additional insights from the same data. Second, speed: there's no waiting for sample processing — analysis begins as soon as you upload your raw data file. Third, and increasingly important in 2026: privacy.
DeepDNA is headquartered in Europe and built from the ground up for GDPR compliance. Your genetic data is processed under European data protection law, which provides substantially stronger protections than US federal law — particularly relevant after the 23andMe bankruptcy demonstrated how easily genetic data can change hands in the US legal system. For context on why this matters, see our analysis of 23andMe alternatives in Europe.
What DeepDNA offers:
- Health and trait reports derived from your existing raw data
- Pharmacogenomics analysis (how your genes may affect drug metabolism)
- Regular report updates as new research is published — without needing a new test
- Full data portability and deletion rights under GDPR
Where DeepDNA has limitations: It can only analyze the SNPs present in your raw data file. If your original test didn't genotype a particular variant, DeepDNA can't report on it. The platform also doesn't offer ancestry composition or relative matching — its focus is health, traits, and pharmacogenomics.
Who it's best for: Anyone who already has raw data from a consumer DNA test and wants deeper health insights, pharmacogenomics analysis, or a privacy-respecting platform — especially users in Europe.
Head-to-Head: Which Service Wins by Category?
Ancestry & Genealogy → AncestryDNA
No contest. AncestryDNA's 25 million-sample database and 19 billion historical records create a genealogical network that no competitor can match. 23andMe offers decent ancestry estimates but lacks the documentary records integration. DeepDNA doesn't compete in this category.
Health Reports → 23andMe (with caveats)
23andMe has the only FDA-authorized DTC health reports, covering genetic health risks, carrier screening, and pharmacogenetics. However, these reports cover a limited set of variants — they're a starting point, not a clinical-grade assessment. DeepDNA provides health analysis from raw data without requiring a new test but doesn't carry FDA authorization. If you need clinically validated health reports, consult a healthcare provider who can order clinical-grade testing.
Privacy & Data Control → DeepDNA
The 23andMe bankruptcy revealed a structural vulnerability in US-based genetic data storage: corporate restructuring can override individual privacy preferences. AncestryDNA hasn't faced a similar crisis but operates under the same US legal framework. DeepDNA's European base and GDPR architecture provide the strongest data protection guarantees currently available in consumer genomics.
Value for Money → DeepDNA (if you already have raw data)
If you've already taken a 23andMe or AncestryDNA test, DeepDNA extracts additional insights from your existing data at no additional sample cost. If you haven't taken any test yet, AncestryDNA at $99 offers the best entry point for ancestry, while 23andMe at $199 is the only option for FDA-authorized health reports.
European Users → DeepDNA
For users in the EU, GDPR compliance isn't a nice-to-have — it's a legal right. DeepDNA was built for this. 23andMe and AncestryDNA both process data in the US, which creates cross-border data transfer complexities under GDPR. European users concerned about where their genetic data is stored and processed have a clear advantage with a European-based service.
The Privacy Question That Matters Most
The 23andMe bankruptcy forced the entire industry to confront an uncomfortable truth: genetic data collected by consumer companies doesn't have the same legal protections as medical records collected by healthcare providers.
In the US, HIPAA doesn't apply to DTC genetic testing companies because they aren't healthcare providers. The Genetic Information Nondiscrimination Act (GINA) prevents genetic discrimination in health insurance and employment but doesn't govern what happens to your data if the company storing it goes bankrupt or gets acquired.
In Europe, GDPR classifies genetic data as a "special category" requiring explicit consent for processing. Under GDPR, you have the right to request deletion, portability, and to object to your data being transferred without your consent. This distinction became practically relevant in 2025 when European regulators challenged the cross-border implications of the 23andMe data transfer.
If genetic data privacy matters to you, the platform's legal jurisdiction is as important as its technology. For a detailed breakdown, read our guide on GDPR and your genetic data.
Frequently Asked Questions
Can I use my 23andMe raw data with DeepDNA?
Yes. You can download your raw data file from your 23andMe account and upload it to DeepDNA for additional analysis. The same applies to AncestryDNA raw data. See our guide on what to do with your 23andMe raw data for step-by-step instructions.
Is 23andMe still safe to use after the bankruptcy?
The service continues to operate under TTAM Research Institute. Your reports and account access remain intact. However, the data transfer during bankruptcy raised legitimate privacy concerns. If you're uncomfortable with the new ownership, you can request data deletion from your account settings.
Which DNA test is most accurate?
All three platforms achieve greater than 99.5% genotyping accuracy for common SNPs. Accuracy differences between services are minimal for the variants they test. The real question is what each service does with that data — the analysis pipeline and report quality vary significantly. For more on how the testing process works, see our explainer on how DNA testing works.
Should I take both 23andMe and AncestryDNA?
It depends on your goals. If you want both health reports and maximum genealogical coverage, taking both tests is the most complete approach — but expensive at ~$300 combined. A cost-effective alternative: take AncestryDNA for genealogy ($99), download your raw data, and upload it to DeepDNA for health and pharmacogenomics analysis.
What is the best DNA test for European ancestry?
AncestryDNA has the largest European reference populations and the most granular regional breakdowns. For health analysis with European data protection, DeepDNA is the strongest option. Our comparison of 23andMe alternatives for European users covers this in detail.
The Bottom Line
There's no single "best DNA test" — it depends on what you want.
- For genealogy and family connections: AncestryDNA's database and historical records are unmatched.
- For FDA-authorized health reports from a new test: 23andMe remains the only option, though the privacy trade-offs after bankruptcy deserve careful consideration.
- For getting more from data you already have: DeepDNA analyzes your existing raw data with a focus on health, pharmacogenomics, and privacy — built in Europe, for Europeans and anyone who values data sovereignty.
The most important insight from 2025's upheaval: your DNA doesn't change, but the companies holding your genetic data can. Choose a platform whose data practices you trust for the long term, not just for today. For a broader understanding of what your genome can tell you, start with our complete guide to DNA analysis.
Originally published at deepdna.ai
Top comments (0)